HYTN Announces Proposed Spin-Out of BPC-157 Peptide Drug Development Business - Yahoo Finance

VANCOUVER, British Columbia, April 23, 2026 (GLOBE NEWSWIRE) -- HYTN Innovations Inc. (CSE: HYTN) (OTC Pink: HYTNF) (FSE: 85W0) ("HYTN" or the "Company") announces that its Board of Directors has approved the spin-out of an internally developed peptide drug development business into a dedicated new company ("SpinCo"). As part of the proposed spin-out, SpinCo is expected to complete a concurrent financing to fund the next phase of its development and to pursue a public listing on the Canadian Securities Exchange (the "CSE"), subject to regulatory approvals and market conditions.

The proposed spin-out is intended to separate from HYTN a peptide-focused drug development business centered on the pre-clinical development of a subcutaneous injectable BPC-157 drug candidate for refractory ligament disorders. HYTN has built this business internally and has assembled the manufacturing, operating, regulatory and quality framework required to advance the program into the next stage of clinical development.

The business proposed to be transferred to SpinCo includes the assets, Good Manufacturing Practices ("GMP") operating systems, regulatory framework and related know-how comprising HYTN's peptide drug development business, together with the documentation, clinical-support processes and infrastructure required to advance the program.

HYTN has selected a Canadian GMP-certified sterile pharmaceutical contract manufacturing organization for the initial manufacture of sterile BPC-157 drug product and has selected an approved medical device platform intended to support dose-controlled subcutaneous administration. HYTN has also established the framework required to support advancement through both Clinical Trial Application ("CTA") and Special Access Program ("SAP") pathways and has been structuring the program in accordance with Health Canada, the European Medicines Agency and the U.S. Food and Drug Administration principles to support future regulatory optionality.

HYTN has developed the pharmaceutical-grade infrastructure required to manage the program in full compliance with GMP standards. This includes systems for manufacturing control, packaging and labelling, batch release, warehousing, controlled distribution, traceability, documentation and quality oversight. In addition, the Company is advancing specialized clinic-facing support systems, including logistics, documentation assistance and case coordination, to reduce the administrative burden on physicians participating in Health Canada's Special Access Program (SAP) relating to peptide dispensation, while preserving future supply chain flexibility through additional GMP activities.